ZCM
SUPN icon

Zebra Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Zebra Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,446
Closed -$438K – 275
2020
Q2 		$438K Sell
18,446
-4,296
-19% -$94.9K 0.63% 45
2020
Q1 		$409K Sell
22,742
-2,421
-10% -$50.9K 0.66% 48
2019
Q4 		$597K Buy
25,163
+11,559
+85% +$281K 0.53% 54
2019
Q3 		$373K Buy
13,604
+4,206
+45% +$125K 0.41% 88
2019
Q2 		$311K Buy
+9,398
New +$322K 0.16% 260

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Zebra Capital Management's SUPN Position: Q3 2020 in Review

Zebra Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2020, closing a stake of 18,446 shares — an estimated $438K sold.

Zebra Capital Management first reported a position in SUPN in Q2 2019 and held it in 5 quarters. The position peaked at $597K in Q4 2019. 209 funds tracked by Wall St. Rank hold SUPN as of Q3 2020.

  • Zebra Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Zebra Capital Management sold 18,446 Supernus Pharmaceuticals shares in Q3 2020, an estimated $438K.
  • Zebra Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Zebra Capital Management's Supernus Pharmaceuticals position peaked at $597K in Q4 2019.
  • 209 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2020.

Based on Zebra Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.